



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Liraglutide + Insulin Degludec > Printer-friendly PDF

Liraglutide + Insulin Degludec

Trade Name:

Xultophy

Manufacturer/Distributor:

Novo Nordisk

Classification:

Incretin mimetic + insulin

ATC Class:

A10AE56 - insulin degludec + liraglutide

Status:

active

Notice of Compliance (yyyy/mm/dd):

2018/04/11

Date Marketed in Canada (yyyy/mm/dd):

2018/06/06

Presentation:

Injection: per 1 mL: insulin degludec 100 IU, liraglutide 3.6 mg. DIN: 02474875

Comments:

This combination product is indicated as an adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control.

Keywords: insulin degludec

liraglutide

diabetes mellitus: type 2

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

<Any>

?

Search Terms:

Apply

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Aztreonam</u>	Cayston	Antibacterial	2009/11/11
<u>Baloxavir marboxil</u>	Xofluza	Antiviral agent	2020/02/19
<u>Baricitinib</u>	Olumiant	Immunosuppressant	2018/08/17
<u>Belimumab</u>	Benlysta	Immunosuppressant	2011/10/01
<u>Bendamustine</u>	Treanda	Antineoplastic agent	2012/09/12
<u>Benralizumab</u>	Fasenra	Respiratory agent	2018/03/28
<u>Benzocaine</u>	Orajel teething products		2018/05/23
<u>Besifloxacin</u>	Besivance	Fluoroquinolone	2010/01/27
<u>Betamethasone valerate</u>	Beteflam	Anti-inflammatory agent	2016/04/05
<u>Bilastine</u>	Blexten	Antihistamine	2016/12/02
<u>Boceprevir</u>	Victrelis	Hepatitis C virus protease inhibitor	2011/07/29
<u>Brexipiprazole</u>	Rexulti	Antipsychotic agent	2017/04/20
<u>Brigatinib</u>	Alunbrig	Antineoplastic agent	2018/07/26
<u>Brimonidine</u>	Onreltea	alpha-2 adrenergic receptor antagonist for rosacea	2014/04/23
<u>Brivaracetam</u>	Brivlera	Antiepileptic agent	2016/05/10
<u>Brolucizumab</u>	Beovu	Antineovascularisation agent	2020/05/15
<u>Buprenorphine</u>	BuTrans	Opioid analgesic	2010/03/05
<u>Buprenorphine</u>	Belbuca	Opioid analgesic	2018/01/17
<u>Buprenorphine</u>	Probuphine	Opiate partial agonist	2018/04/18
<u>Buprenorphine</u>	Sublocade	Partial opioid agonist	2019
<u>Burosumab</u>	Crysvita	Fibroblast growth factor 23 (FGF23) Inhibitor	2018/12/05
<u>C1 esterase inhibitor, human</u>	Berinert	C1-inhibitor	2010/10/08
<u>Cabazitaxel</u>	Jevtana	Antineoplastic agent	2011/06

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Cabotegravir</u>	Vocabria	Antiretroviral agent	2020/03/19
<u>Cabotegravir + rilpivirine</u>	Cabenuva	Antiretroviral agent	2020/03/19
<u>Cabozantinib</u>	Cabometyx	Antineoplastic agent	2018/09/14
<u>Calcitonin salmon nasal spray</u>	Miacalcin NS, Sandoz Calcitonin NS, Apo-Calcitonin NS	Bone metabolism regulator	
<u>Calcitriol</u>	Rocaltrol oral solution	Vitamin D analogue	
<u>Canagliflozin</u>	Invokana	antihyperglycemic agent	2014/06/25
<u>Canakinumab</u>	Ilaris	Immunomodulatory agent - selective interleukin-1 beta inhibitor	2010/05/03
<u>Caplacizumab</u>	Cablivi	Antithrombotic agent	2020/09/04
<u>Cefotaxime</u>	Claforan	Cephalosporin antibiotic	2016/11/09
<u>Ceftobiprole</u>	Zevtera	Cephalosporin antibiotic	2018/03/20
<u>Ceftobiprole medocaril</u>	Zeftera	Cephalosporin antibiotic	2010/04/16
<u>Cemiplimab</u>	Libtayo	Antineoplastic agent	2019/05/24
<u>Certolizumab pegol</u>	Cimzia	Biological response modifier	2009/08/31

« [first](#) [previous](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [?](#) [next](#) [?](#) [last](#) »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷməkʷyɛm (Musqueam), Skwxwú7mesh Uxwumixw (Squamish Nation), and sʷlʷtʷaʷ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and

applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-05-20 21:06): <http://www.dpic.org/druglisting/liraglutide-insulin-degludec>